Study guide
2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
Key Takeaways Explain This Topic AI
For people exposed through receptive vaginal sex, HIV PrEP options are daily oral TDF/FTC, injectable cabotegravir every 2 months, and twice-yearly subcutaneous lenacapavir (FDA-approved June 2025); oral TAF/FTC is not approved for this exposure.
CDC's 2024 doxycycline post-exposure prophylaxis (doxy-PEP) recommendation covers men who have sex with men and transgender women, not cisgender women.
CDC recommends hepatitis B screening of all adults at least once with a triple panel (HBsAg, anti-HBs, total anti-HBc) and hepatitis C screening of all adults at least once and during every pregnancy.
Mycoplasma genitalium causes persistent cervicitis and PID; CDC's resistance-guided regimen is doxycycline for 7 days followed by moxifloxacin 400 mg daily for 7 days.
Pubic lice are treated with permethrin 1% cream rinse and scabies with permethrin 5% cream (ivermectin is an alternative outside pregnancy), plus decontamination of bedding and treatment of close contacts.
Last updated: October 2026
HIV Screening
USPSTF (grade A): Screen everyone aged 15–65 at least once, younger and older people at increased risk, and every pregnant person . CDC recommends opt-out screening for ages 13–64.
Test: A laboratory 4th-generation HIV-1/2 antigen/antibody immunoassay, followed by a differentiation assay; a reactive screen with a negative differentiation result needs HIV-1 RNA testing to detect acute infection.
Window period: Most antigen/antibody assays detect infection about 18–45 days after exposure; nucleic acid tests detect it sooner.
Rescreen at least annually with ongoing risk and repeat in the third trimester for pregnant people at risk or in high-incidence areas.
HIV Pre-Exposure Prophylaxis (PrEP)
The USPSTF (2023, grade A) recommends offering PrEP to anyone at increased risk, such as a partner with HIV whose viral load is not suppressed, inconsistent condom use with partners of unknown status, a recent bacterial STI, or injection drug use.
Agent Dosing Key Points for Women
TDF/FTC (oral) One tablet daily Approved for all exposures; daily dosing reaches maximal cervicovaginal tissue levels after about 20–21 days (about 7 days for rectal tissue); check creatinine and hepatitis B status because stopping it can flare HBV
TAF/FTC (oral) One tablet daily Not approved for people exposed through receptive vaginal sex
Cabotegravir (CAB-LA) IM injections at 0 and 1 month, then every 2 months Superior to oral PrEP in trials of cisgender women; needs an HIV RNA test before each injection
Lenacapavir Subcutaneous injections every 6 months after an oral loading phase FDA-approved June 2025; 100% efficacy among cisgender women in PURPOSE 1; CDC now recommends it as a PrEP option
Before any PrEP, document a negative HIV test and screen for STIs every 3 months (oral) or at injection visits. TDF/FTC is considered safe during conception, pregnancy, and breastfeeding, so PrEP should continue if an at-risk patient becomes pregnant.
Post-Exposure Prophylaxis (nPEP)
Start a 28-day, 3-drug regimen as soon as possible and no later than 72 hours after a high-risk exposure. CDC's 2025 update prefers single-tablet bictegravir/emtricitabine/tenofovir alafenamide. Transition directly to PrEP at the end of PEP if risk continues.
Doxycycline PEP: Not for Cisgender Women
CDC's 2024 guidance recommends doxycycline 200 mg within 72 hours after condomless sex to prevent syphilis, gonorrhea, and chlamydia only for men who have sex with men and transgender women with a bacterial STI in the past year. A trial among cisgender women in Kenya showed no benefit, so doxy-PEP is not recommended for cisgender women.
Hepatitis B
Screening (CDC 2023): Test every adult at least once with the triple panel (HBsAg, anti-HBs, total anti-HBc), and every pregnancy with HBsAg.
Vaccination: Universal for adults aged 19–59; for those 60 and older with risk factors or on request.
- HBsAg Anti-HBc (total) Anti-HBs Interpretation
- Negative Negative Positive Immune from vaccination
- Negative Positive Positive Immune from resolved natural infection
- Positive Positive (IgM) Negative Acute infection
- Positive Positive (IgG) Negative Chronic infection (HBsAg >6 months)
- Negative Negative Negative Susceptible: vaccinate
Negative Positive Negative Isolated core antibody: resolved infection, window period, or false positive; check HBV DNA
Chronic infection needs HBV DNA, liver tests, referral, and hepatocellular carcinoma surveillance when indicated. In pregnancy, tenofovir from 28–32 weeks lowers transmission when HBV DNA exceeds 200,000 IU/mL, and the newborn gets HBIG plus vaccine within 12 hours.
Hepatitis C
Screening (CDC 2020): All adults 18 and older at least once, every pregnancy , and periodically with ongoing risk such as injection drug use.
A reactive antibody test needs HCV RNA to confirm current infection; antibody persists after cure or spontaneous clearance.
Direct-acting antivirals (8–12 weeks) cure more than 95%. Sexual transmission is uncommon but rises with HIV coinfection and traumatic sexual practices.
Mycoplasma genitalium
A cause of persistent or recurrent cervicitis , urethritis, and some PID. Test with NAAT when cervicitis persists after standard therapy; routine screening of asymptomatic women is not recommended. Because macrolide resistance is common, CDC's 2021 regimen is doxycycline 100 mg twice daily for 7 days, then moxifloxacin 400 mg daily for 7 days . If resistance testing shows macrolide sensitivity, doxycycline is followed by azithromycin (1 g, then 500 mg daily for 3 days).
Ectoparasites and Molluscum
Condition Presentation Treatment
Pubic lice ( Pthirus pubis ) Pubic itching, visible lice and nits on hair shafts Permethrin 1% cream rinse, washed off after 10 minutes; retreat in 7–10 days if needed; launder bedding at high heat; treat partners within the past month
Scabies ( Sarcoptes scabiei ) Intense nocturnal itching, burrows in web spaces, wrists, waistline, and genitals Permethrin 5% cream neck to toes, washed off after 8–14 hours, repeat in 1–2 weeks; oral ivermectin 200 mcg/kg repeated in 14 days is an alternative but is avoided in pregnancy; itching can persist 2 weeks after cure
Molluscum contagiosum Firm, dome-shaped, umbilicated papules on the genitals or thighs in adults Self-limited; cryotherapy or curettage; extensive lesions should prompt HIV testing